Open AccessThe AMPA receptor antagonist perampanel suppresses epileptic activity in human focal cortical dysplasia
Author(s) -
Brito da Silva Anderson,
Pennifold Jane,
Henley Ben,
Chatterjee Koustav,
Bateman David,
Whittaker Roger W.,
Joshi Abhijit,
Kumar Hrishikesh,
Nicholson Claire,
Baker Mark R.,
Greenhill Stuart D.,
Walsh Richard,
Seri Stefano,
Jones Roland S. G.,
Woodhall Gavin L.,
Cunningham Mark O.
Publication year - 2022
Publication title -
epilepsia open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.247
H-Index - 16
ISSN - 2470-9239
DOI - 10.1002/epi4.12549
Subject(s) - perampanel , ampa receptor , epilepsy , cortical dysplasia , glutamatergic , neuroscience , antagonist , glutamate receptor , medicine , pharmacology , receptor , biology
Focal cortical dysplasia (FCD) is one of the most common malformations causing refractory epilepsy. Dysregulation of glutamatergic systems plays a critical role in the hyperexcitability of dysplastic neurons in FCD lesions. The pharmacoresistant nature of epilepsy associated with FCD may be due to a lack of well‐tolerated and precise antiepileptic drugs that can target glutamate receptors. Here, for the first time in human FCD brain slices, we show that the established, noncompetitive α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptor antagonist, perampanel has potent antiepileptic action. Moreover, we demonstrate that this effect is due to a reduction in burst firing behavior in human FCD microcircuits. These data support a potential role for the treatment of refractory epilepsy associated with FCD in human patients.